title: Vaccination against gonadotropin-releasing factor (GnRF) with Bopriva significantly decreases testicular development, serum testosterone levels and physical activity in pubertal bulls.
abstract: The aim of this study was to evaluate the effects of vaccination against gonadotropin-releasing factor (GnRF) on testicular development, testosterone secretion, and physical activity in pubertal bulls. The experiment was performed using 44 bulls aged between 6 and 7 mo. Twenty-three animals were vaccinated twice 4 wk apart with 1 mL of Bopriva (Pfizer, Animal Health, Parkville, Australia) and 21 bulls served as matched controls. Serum GnRF antibody titer and testosterone concentration as well as body weight and scrotal circumference were determined in all bulls for 24 wk from the first vaccination. In addition, physical activity was analyzed in 11 vaccinated and in 10 control animals using the ALPRO DeLaval activity meter system (DeLaval AG, Sursee, Switzerland). The results show that vaccination significantly (P < 0.05) influenced all parameters evaluated except body weight. Antibody titers to GnRF began to rise 2 wk after the first vaccination and reached peak values 2 wk after the second injection. Significant group differences in anti-GnRF titer were present for 22 wk following the first vaccination. Testosterone concentrations were significantly lower between weeks 6 to 24 after first vaccination in bulls with Bopriva compared with control animals. In vaccinated bulls testicular development was impaired after the second injection and scrotal circumference was significantly smaller between weeks 8 to 24 after first vaccination. Physical activity of vaccinated bulls was reduced after the booster injection with significant group differences for a continuous period of 106 days. In conclusion, vaccination against GnRF with Bopriva in pubertal bulls decreased testosterone levels in peripheral blood, testicular development, and physical activity but did not affect weight gain.
authors.affiliation: Clinic of Reproductive Medicine, Vetsuisse-Faculty University of Zürich, Zürich, Switzerland. fjanett@vetclinics.uzh.ch
authors.forename: F
authors.initials: F
authors.lastname: Janett
authors.forename: T
authors.initials: T
authors.lastname: Gerig
authors.forename: A C
authors.initials: AC
authors.lastname: Tschuor
authors.forename: S
authors.initials: S
authors.lastname: Amatayakul-Chantler
authors.forename: J
authors.initials: J
authors.lastname: Walker
authors.forename: R
authors.initials: R
authors.lastname: Howard
authors.forename: H
authors.initials: H
authors.lastname: Bollwein
authors.forename: R
authors.initials: R
authors.lastname: Thun
mesh_terms: D000818:Animals; D000906:Antibodies / Q000032:analysis / Q000097:blood; D001835:Body Weight / Q000187:drug effects / Q000502:physiology; D002417:Cattle; D007987:Gonadotropin-Releasing Hormone / Q000276:immunology*; D008297:Male; D009043:Motor Activity / Q000187:drug effects*; D009929:Organ Size / Q000187:drug effects; D012611:Scrotum / Q000187:drug effects / Q000254:growth & development; D012741:Sexual Maturation / Q000187:drug effects / Q000502:physiology; D013737:Testis / Q000187:drug effects* / Q000254:growth & development; D013739:Testosterone / Q000097:blood*; D014611:Vaccination / Q000662:veterinary; D022642:Vaccines, Contraceptive / Q000494:pharmacology*
chemical_list: D000906:Antibodies; D022642:Vaccines, Contraceptive; D007987:Gonadotropin-Releasing Hormone; D013739:Testosterone